NMRA Jumps 46% as EPS Revisions Fuel Biotech Rally; REPL, BUR Follow
Neumora Therapeutics (NMRA) led gainers with a 46.1% surge since its October 29 EPS estimate revision, while Replimune (REPL) rose 28.8% after beating Q2 estimates and launching its melanoma therapy TUDRIQEV. Burford Capital (BUR) climbed 23.1% following a strong Q3 beat and debt reduction, and Rhythm Pharmaceuticals (RYTM) gained 18.9% on accelerating IMCIVREE sales and expanded NICE guidance.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| NMRA | Healthcare | 2026-10-29 | +1.1pp | +46.1% |
| REPL | Healthcare | 2026-10-28 | +1.4pp | +28.8% |
| BUR | Financial | 2026-10-28 | N/A | +23.1% |
| RYTM | Healthcare | 2026-10-29 | N/A | +18.9% |
| CSGP | Real Estate | 2026-10-28 | N/A | +18.3% |
Why did NMRA stock jump in November 2026?
NMRA jumped 46.1% (from $0.39 to $0.57) after analysts raised its forward EPS growth estimate from 30.1% to 31.1% on October 29.
The micro-cap healthcare stock was detected by our EPS revision screener at $0.39, and the subsequent rally reflects growing confidence in the company's pipeline despite no earnings-related news in the window. The revision, though modest at 1.1 percentage points, triggered outsized buying in a thinly traded name, amplifying the price move.
NMRA EPS revision history → · Screener snapshot from 2026-10-29 →
FAQ: NMRA
Why did NMRA stock jump?
NMRA jumped 46.1% from $0.39 to $0.57 after an upward revision to its forward EPS growth estimate from 30.1% to 31.1% on October 29, 2026.
Is NMRA a buy after the rally?
The 46.1% gain reflects a strong reaction to a modest EPS revision, but NMRA remains a micro-cap with no recent earnings news, so investors should weigh the lack of fundamental catalysts.
What is NMRA's EPS growth estimate?
NMRA's next-year EPS growth estimate was revised to 31.1% from 30.1% on October 29, 2026.
Why did REPL stock jump in November 2026?
REPL surged 28.8% (from $16.06 to $20.69) after analysts raised its forward EPS growth estimate from 33.9% to 35.3% on October 28.
The move was reinforced by Replimune's fiscal Q2 earnings beat, with a loss of $0.54 per share versus the $0.70 consensus, and the commercial launch of TUDRIQEV for advanced melanoma. More than 15 institutions have prescribed the therapy since its October 6 availability, marking the company's transition from pre-revenue to commercial-stage.
REPL EPS revision history → · Screener snapshot from 2026-10-28 →
FAQ: REPL
Why did REPL stock jump?
REPL jumped 28.8% from $16.06 to $20.69 after an EPS growth estimate revision to 35.3% from 33.9% on October 28, 2026, and a Q2 earnings beat.
What caused REPL's surge?
REPL's surge was driven by a 22.9% earnings beat and the launch of TUDRIQEV, with over 15 institutions prescribing the melanoma therapy since October 6.
Is REPL a buy after the rally?
REPL's investment case now hinges on TUDRIQEV's revenue conversion, with management not yet quantifying sales, but the strong launch metrics and EPS revision support further upside.
Why did BUR stock jump in November 2026?
BUR climbed 23.1% (from $3.38 to $4.16) after its next-year EPS growth estimate was revised to 108.2% on October 28.
The litigation financier then reported Q3 earnings of $0.10 per share, beating the $0.09 consensus, with revenue of $146.91 million topping estimates by 47.4%. Burford also announced $100 million of debt reduction and retired its nearest-term maturity, improving its balance sheet amid a pause in new commitments.
BUR EPS revision history → · Screener snapshot from 2026-10-28 →
FAQ: BUR
Why did BUR stock jump?
BUR jumped 23.1% from $3.38 to $4.16 after an EPS growth estimate revision to 108.2% on October 28, 2026, and a Q3 earnings beat.
What caused BUR's surge?
BUR's surge was driven by a Q3 earnings beat of 11.1% and revenue beat of 47.4%, along with $100 million of debt reduction.
Is BUR a buy after the rally?
BUR's strong Q3 results and balance-sheet repair support the stock, but management's pause on new commitments to cut debt may limit near-term growth.
Why did RYTM stock jump in November 2026?
RYTM rose 18.9% (from $93.07 to $110.68) after its next-year EPS growth estimate was set at 78.1% on October 29.
The company then reported Q3 revenue of $92.13 million, beating the $84.47 million consensus, with IMCIVREE sales up 29% sequentially. Rhythm also secured a five-year $750 million term loan and received expanded NICE guidance for IMCIVREE in adults with Bardet-Biedl syndrome, broadening its European market access.
RYTM EPS revision history → · Screener snapshot from 2026-10-29 →
FAQ: RYTM
Why did RYTM stock jump?
RYTM jumped 18.9% from $93.07 to $110.68 after an EPS growth estimate of 78.1% on October 29, 2026, and a Q3 revenue beat.
What caused RYTM's surge?
RYTM's surge was driven by 29% sequential IMCIVREE sales growth to $92.1 million, a $750 million term loan, and expanded NICE guidance for Bardet-Biedl syndrome.
What is RYTM's EPS growth estimate?
RYTM's next-year EPS growth estimate is 78.1%, reflecting accelerating IMCIVREE sales and expanding reimbursement.
Why did CSGP stock jump in November 2026?
CSGP gained 18.3% (from $27.54 to $32.58) after its next-year EPS growth estimate was set at 26.1% on October 28.
The real estate data provider then raised its near-term U.S. retail forecast and upgraded its multifamily growth outlook, with Apartments.com projecting rent growth of 1.4% through Q4 and 2.6% by Q4 2027. The revisions signal strengthening fundamentals in commercial real estate, supporting CoStar's earnings trajectory.
CSGP EPS revision history → · Screener snapshot from 2026-10-28 →
FAQ: CSGP
Why did CSGP stock jump?
CSGP jumped 18.3% from $27.54 to $32.58 after an EPS growth estimate of 26.1% on October 28, 2026, and upgraded multifamily and retail forecasts.
What caused CSGP's surge?
CSGP's surge was driven by an upgraded multifamily rent growth forecast to 2.6% by Q4 2027 and a raised near-term retail forecast.
Is CSGP a buy after the rally?
CSGP's improved real estate forecasts and 26.1% EPS growth estimate support the rally, but the stock's 18.3% gain may already reflect much of the good news.
Today's top performers highlight a broad rally across healthcare and financials, with EPS revisions and earnings beats driving outsized gains in small- and mid-cap stocks. The market is rewarding companies that deliver tangible commercial progress, from REPL's therapy launch to BUR's debt reduction.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →